Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entheon Biomedical Corp ENTBF


Primary Symbol: C.ENBI

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.

Recent & Breaking News (CSE:ENBI)

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

GlobeNewswire December 7, 2022

Entheon (CSE:ENBI) closes sale of DMT clinical assets

John Ballem  July 11, 2022

Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets

Newsfile July 11, 2022

Entheon (CSE:ENBI) sells DMT clinical assets and files provisional patents

Azuka Onwuka June 7, 2022

Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents

Newsfile June 7, 2022

Ehave subsidiary partners with Entheon Biomedical (CSE:ENBI) in psychedelics research

Azuka Onwuka June 1, 2022

Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

GlobeNewswire June 1, 2022

Entheon Biomedical (CSE:ENBI) announces $3M non-brokered private placement

John Ballem  April 5, 2022

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Newsfile April 5, 2022

Entheon Biomedical (CSE:ENBI) expands its psychedelics genetic test panel

Brieanna McCutcheon  March 29, 2022

Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform

Newsfile March 29, 2022

Entheon Biomedical (CSE:ENBI) announces first patient enrollment in Phase 1 study of DMT

Brieanna McCutcheon  March 15, 2022

Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT

Newsfile March 15, 2022

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

Newsfile February 24, 2022

Entheon Biomedical (CSE:ENBI) partners with Wavepaths on ketamine study

Caroline Egan  February 16, 2022

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

Newsfile February 16, 2022

Entheon Biomedical (CSE:ENBI) approved for DMT clinical trial

Trevor Abes  February 3, 2022

Entheon Biomedical Announces the Approval of DMT Clinical Trial

Newsfile February 3, 2022

Entheon Biomedical (CSE:ENBI) subsidiary enters agreement with Psychedelics Today

Caroline Egan  January 18, 2022

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Newsfile January 18, 2022